[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Madigan Army Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":155},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,75,104,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100618719","enhancing-operational-readiness-with-digital-self-managed-cognitive-behavioral-therapy-for-insomnia-cbti-100618719",false,"NCT07335276","Enhancing Operational Readiness With Digital Self-Managed Cognitive Behavioral Therapy for Insomnia (CBTI)","Enhancing Operational Readiness With Digital Self-Managed Cognitive Behavioral Therapy for Insomnia (CBTI): A Pilot Randomized Controlled Trial for Service Members","Inclusion Criteria:\n\n* Active Duty, Reservist, Army National Guard\n* Ages 18-55 years\n* Own a smart phone\n* Internet access\n\nExclusion Criteria:\n\n* Insomnia Severity Score \\> or equal to 10\n* PHQ-8 score \\\u003C20\n* Untreated sleep disorders (sleep apnea, narcolepsy, parasomnias)\n* Pregnancy\n* Working rotating Shifts\n* Caring for a newborn \\\u003C3 months old\n* Currently receiving cognitive behavioral therapy for insomnia\n* Received cognitive behavioral therapy for insomnia in the last 6 months","ALL","18 Years","55 Years",{"count":20,"type":21},144,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this pilot clinical trial is to evaluate the effectiveness and delivery method of a CBTI self-managed digital mobile application in service members.\n\nThe main questions it aims to answer are:\n\nRQ1. Will the delivery of CBTI via a self-managed mobile application over five weeks improve sleep outcomes for service members?\n\nRQ2. Will the delivery of CBTI via a self-managed mobile application over five weeks improve secondary outcomes (sleep-related impairment, depression, PTSD symptoms, and quality of life) for service members?",[27,28,29],"Insomnia","Depression - Major Depressive Disorder","PTSD",[27,31,32,33],"Service Members","Cognitive Behavioral Therapy for Insomnia","Digital Application","NOT_YET_RECRUITING","2026-01-20",{"date":37,"type":38},"2026-01-22","ACTUAL",{"date":40,"type":21},"2026-03-01",{"date":42,"type":21},"2028-10-02",{"name":44,"class":45},"Madigan Army Medical Center","FED",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100608305","evaluating-response-to-vitamin-d3-and-k2-supplementation-in-healthcare-personnel-100608305","NCT07199829","Evaluating Response to Vitamin D3 and K2 Supplementation in Healthcare Personnel","A Double-Blind Randomized Controlled Trial Evaluating Response to Vitamin D3 and K2 Supplementation Through Inflammatory Markers and the Gut Microbiome in Healthcare Personnel","Inclusion Criteria:\n\n* able to read and understand English\n* 25 OHD serum level equal to or less than 30 ng\u002FmL\n* willing to discontinue vitamin D3 and\u002For K2 supplements for 4.5 months\n* military beneficiary (Active Duty, Retired, Dependent)\n* remaining employed at workplace for 6 months\n\nExclusion Criteria:\n\n* Diagnosed medical condition that prevents nutrient absorption from food (e.g. Inflammatory Bowel Disease, Celiac Disease, post-Roux-en-Y\u002FGastric sleeve surgery)\n* Pregnant or breastfeeding\n* Current antibiotic use or within past 3 months\n* Current anticoagulant use or within past 3 months\n* Current weight loss or fat malabsorption medication use (e.g. Glucagon-Like Peptide 1 agonists, Orlistat)\n* Allergies or sensitivities to methylcellulose, vitamin D (D3, D2), or vitamin K (K2, Menaquinone-4, Menaquinone-7)",true,"69 Years",{"count":56,"type":21},96,[24],"The main purpose of this research study is to learn about the effects of supplemental vitamin D3 and vitamin K2 on blood levels and the gut microbial community, called the gut microbiome. There are many influences on blood levels of vitamin D and K to include your dietary intake, lifestyle behaviors (physical activity, sleep), genetic alterations in metabolism of these vitamins, and the gut microbial abundance and diversity. You will be asked to take one capsule containing vitamin D3 (125 mcg), vitamin K2 (180 mcg), a combination of vitamins D3 and K2 (same doses as previous), or a placebo powder for 90 days. You will also be asked to complete questionnaires, undergo body composition and blood pressure measurements, provide blood samples and a stool swab, all on 2 occasions about 3 - 4 months apart. By conducting this study, we aim to identify the frequency of common genetic alterations in vitamins D and K metabolism and establish the impact on the gut microbiome for the first time. Your participation in this study will last about 4 - 6 months and include up to 3 visits.",[60,61],"Hypovitaminosis D","Hypovitaminosis",[60,63,64],"Hypovitaminosis K","Gut microbiome","RECRUITING","2025-09-22",{"date":68,"type":38},"2025-09-30",{"date":70,"type":38},"2025-03-27",{"date":72,"type":21},"2026-03",{"name":44,"class":45},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":74},"100578556","phase-4-simethicone-as-part-of-eras-in-bariatric-surgery-patients-100578556","NCT06812832","Simethicone as Part of ERAS in Bariatric Surgery Patients","Simethicone as Part of an Enhanced Recovery After Surgery (ERAS) Protocol","Inclusion Criteria:\n\n* Foregut procedures\n\nExclusion Criteria:\n\n* Non-foregut procedures\n* Allergy to simethicone\n* Pregnancy or breastfeeding\n* Minors under 18 years of age","89 Years",{"count":84,"type":21},260,[86],"PHASE4","By conducting this study, we hope to assess if simethicone (also known as Gas Relief or GasX) has an effect on improving gas pain and bloating specifically in patients undergoing foregut procedures to include bariatric procedures (sleeve gastrectomy, Roux-en-Y gastric bypass), hiatal hernia, and gastric surgery.\n\nThe purpose of this research is to gather information on the safety and effectiveness of simethicone. Simethicone (more commonly known as Gas Relief or Gas-X) relieves pressure, bloating, and fullness commonly referred to as gas. It is FDA approved. The use of this medication in this research study is consistent with labeling indications.",[89,90,91],"Simethicone","Bariatric Surgery","Post-operative Pain",[89,93,94,95],"Gas-X","Foregut","Post-operative pain","2025-06-11",{"date":98,"type":38},"2025-06-15",{"date":100,"type":38},"2025-04-08",{"date":102,"type":21},"2029-03",{"name":44,"class":45},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":74},"100441163","early-phase-1-antiseptic-effects-on-the-dental-implant-internal-surface-microbiome-100441163","NCT05024760","Antiseptic Effects on the Dental Implant Internal Surface Microbiome","Inclusion Criteria:\n\n* Active duty military\n* 18-55 years old\n* Over 6 months remaining at local duty station\n\nExclusion Criteria:\n\n* Tobacco user\n* Medications that affect soft tissue or bone healing\n* Metabolic disorder that affects soft tissue or bone healing\n* Active periodontal disease",{"count":111,"type":21},150,[113],"EARLY_PHASE1","Soldiers operate in environments that are more likely to lead to oral trauma, risking poor dentition which can directly impact military readiness. Dental restoration can often be accomplished via dental implant insertion. Microbiome-associated complications that result in bone loss, including the micro-leakage of bacterial species proliferating in the dental implant internal cavity, frequently lead to implant failure. Reduction in implant bacterial load may result in a shift of the composition of the microbiome in favor of less pathogenic species, potentially improving dental implant success rates, reducing surgical revisions, and associated cost savings. This study aims to determine how disinfectant gel (hydrogen peroxide or chlorhexidine) insertion into dental implant internal cavities affects implant failure rates, bacterial load and microbiome composition.",[116,117,118,119],"Peri-Implantitis","Peri-implant Mucositis","Implant Infection","Dental Implant Failed","2024-12-19",{"date":122,"type":38},"2024-12-27",{"date":124,"type":38},"2022-07-28",{"date":126,"type":21},"2025-11",{"name":44,"class":45},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":143,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":74},"100416563","phase-4-trigger-point-injection-for-myofascial-pain-syndrome-in-the-low-back-a-randomized-controlled-trial-100416563","NCT04704297","Trigger Point Injection for Myofascial Pain Syndrome in the Low Back: A Randomized Controlled Trial","Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial.","T-PIMPS","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Must have at least 1 trigger point in low back paraspinal muscles.\n3. For exacerbations of chronic low back pain, the pain on presentation must be 1.5 cm above baseline pain on VAS\n\nExclusion Criteria:\n\n1. Allergy or inability to take study medications.\n2. New focal neurologic deficit in lower extremities.\n3. Known active malignancy with bony spinal metastases.\n4. Identifiable spinal, lumbosacral or hip fracture.\n5. History of Fibromyalgia, rheumatoid arthritis, ankylosing spondylitis.\n6. Current use of anticoagulation.\n7. Overlying cellulitis.\n8. Spinal, hip, or pelvic surgery within the past 6 months.\n9. Previous administration of trigger point injections for current episode.\n10. Sciatica-extending down the back of the leg to the heel.\n11. Alternate identifiable cause of participant's acute pain other than myofascial or musculoskeletal pain.\n12. Febrile patients.\n13. Pregnant\n14. Unable to understand English or otherwise unable to provide informed consent (mental handicap, inability to understand instructions, risks, or benefits), or is an at risk population (wounded warrior, resident physicians, prisoners, cadets, midshipmen, or students).",{"count":137,"type":21},180,[86],"Rationale: Low back pain (LBP), or myofascial pain syndrome (MPS) of the low back, accounts for approximately 2.63 million visits in the United States, or 2.3 percent of annual Emergency Department (ED) visits. An estimated 100 billion dollars per year is lost from LBP. Approximately one-third of this is direct costs. Previous studies have established the safety of trigger point injections (TPI). However, the results of these studies are highly heterogeneous regarding TPI's ability to treat pain or improve functional outcomes. The two most promising TPI studies conducted in the ED have been published in the last two years. They both suffered from a small sample size. Additionally, they suffered from a combination of limitations including: lack of randomization, inconsistent medical management, lack of a follow-up assessment, and lack of patient centered functional outcomes. These studies were both two armed and either compared standard medical management to TPI with local anesthetic or TPI with local anesthetic to TPI with Normal Saline (NS). One of these studies concluded that TPI is generally beneficial. The other concluded that TPI with NS is superior.\n\nResearch Hypothesis: The investigators hypothesize that standard therapy (ST) plus TPI with 8 mL of 0.5 percent Bupivacaine is superior to ST alone or ST plus TPI with 8 mL of NS for the treatment of the pain associated with MPS of the low back.\n\nSignificance: This will be the first TPI study to compare ST, to TPI with local anesthetic, and TPI with NS for LBP conducted in an ED. It will also be the first TPI study to incorporate a patient centered functional outcome and patient follow-up after discharge from an ED. TPI's are a popular treatment modality for LBP among many Emergency Medicine Providers. However, to date, there is limited evidence for or against it. The investigators are hopeful that this study will answer whether or not trigger point injections are benefiting patients and, if so, which type of TPI is most beneficial.",[141,142],"Low Back Pain","Myofascial Pain Syndrome Lower Back",[144,141,145,146],"Trigger Point Injection","Myofascial Pain Syndrome","Emergency Department","2021-01-09",{"date":149,"type":38},"2021-01-12",{"date":151,"type":38},"2020-12-28",{"date":153,"type":21},"2022-07-01",{"name":44,"class":45},""]